Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies

Despite remarkable advances in the treatment of multiple myeloma (MM) in the last decades, the prognosis of patients harboring highrisk cytogenetic abnormalities remains dismal as compared to that of standard-risk patients. Proteasome inhibitors have been demonstrated to partially ameliorate the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mina, Roberto, Bonello, Francesca, Petrucci, Maria Teresa, Liberati, Anna Marina, Conticello, Concetta, Ballanti, Stelvio, Musto, Pellegrino, Olivieri, Attilio, Benevolo, Giulia, Capra, Andrea, Gilestro, Milena, Galieni, Piero, Cavo, Michele, Siniscalchi, Agostina, Palumbo, Antonio, Montefusco, Vittorio, Gaidano, Gianluca, Omedé, Paola, Boccadoro, Mario, Bringhen, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018137/
https://www.ncbi.nlm.nih.gov/pubmed/32107329
http://dx.doi.org/10.3324/haematol.2019.243428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018137/
https://www.ncbi.nlm.nih.gov/pubmed/32107329
http://dx.doi.org/10.3324/haematol.2019.243428

Ejemplares similares